536565 NOVELIX

Novelix Pharmaceuticals Share Price

 

 

Start SIP in NOVELIX

Start SIP

Performance

  • Low
  • ₹59
  • High
  • ₹63
  • 52 Week Low
  • ₹25
  • 52 Week High
  • ₹70
  • Open Price₹63
  • Previous Close₹63
  • Volume6,653
  • 50 DMA₹58.88
  • 100 DMA₹54.71
  • 200 DMA₹46.11

Investment Returns

  • Over 1 Month + 13.06%
  • Over 3 Month + 1.29%
  • Over 6 Month + 54.6%
  • Over 1 Year + 142.17%

Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!

Invest Now

Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 59.2
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 108
  • P/B Ratio
  • 3.8
  • Average True Range
  • 3.71
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.14
  • RSI
  • 53.3
  • MFI
  • 47.88

Novelix Pharmaceuticals Financials

Novelix Pharmaceuticals Technicals

EMA & SMA

Current Price
₹61.39
-1.61 (-2.56%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹60.88
  • 50 Day
  • ₹58.88
  • 100 Day
  • ₹54.71
  • 200 Day
  • ₹46.11

Resistance and Support

61.15 Pivot Speed
  • R3 67.38
  • R2 65.22
  • R1 63.31
  • S1 59.24
  • S2 57.08
  • S3 55.17

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Novelix Pharmaceuticals Ltd has an operating revenue of Rs. 127.97 Cr. on a trailing 12-month basis. An annual revenue growth of 578% is outstanding, Pre-tax margin of 0% needs improvement, ROE of 0% is poor and needs improvement. The company has a debt to equity of 53%, which is bit higher. The stock from a technical standpoint is comfortably placed above its key moving averages, around 6% and 39% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 10% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 75 which is a FAIR score but needs to improve its earnings, a RS Rating of 95 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 119 indicates it belongs to a poor industry group of Food-Packaged and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-12 Quarterly Results
2025-11-13 Quarterly Results
2025-08-14 Quarterly Results & A.G.M.
2025-06-24 Others Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company.
2025-05-27 Audited Results

Novelix Pharmaceuticals F&O

Novelix Pharmaceuticals Shareholding Pattern

50.8%
44%
5.2%

Novelix Pharmaceuticals FAQs

Novelix Pharmaceuticals share price is ₹61 As on 18 February, 2026 | 04:01

The Market Cap of Novelix Pharmaceuticals is ₹108.1 Cr As on 18 February, 2026 | 04:01

The P/E ratio of Novelix Pharmaceuticals is 59.2 As on 18 February, 2026 | 04:01

The PB ratio of Novelix Pharmaceuticals is 3.8 As on 18 February, 2026 | 04:01

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23